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Transcription from the HIV-1 long terminal repeat (LTR) is regulated by the viral transactivator Tat, which increases RNA
polymerase II (RNAP II) processivity. Previous reports have demonstrated that phosphorylation of the RNAP II carboxy-
terminal domain by TFIIH and P-TEFb is important for Tat transactivation. Our present results demonstrate that phosphor-
ylation of the RAP74 subunit of TFIIF is also an important step in Tat transactivation. Interestingly, while the general
transcription factor TFIIF is required for both basal and Tat-activated transcription, phosphorylation of the RAP74 subunit
occurs in the presence of Tat and correlates with a high level of transcription activity. Using a biotinylated DNA template
transcription assay, we provide evidence that RAP74 is phosphorylated by TAFII250 during Tat-activated transcription.
Depletion of RAP74 from the HeLa nuclear extract inhibited HIV-1 LTR-driven basal transcription and Tat transactivation. The
addition of TFIIF, reconstituted from recombinant RAP30 and RAP74, to the depleted HeLa nuclear extract resulted in
restoration of Tat transactivation. Of importance, the exogenous RAP74 was rapidly phosphorylated in the presence of Tat.
These results suggest that RAP74 phosphorylation is one important step, of several, in the Tat transactivation cascade.
© 2000 Academic PressINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) encodes
a highly conserved transactivator, Tat, that is expressed
early in the viral life cycle and is essential for viral
replication (Cullen, 1993; Jones and Peterlin, 1994; Gay-
nor, 1995; Karn, 1999; Garber and Jones, 1999; Jeang et
al., 1999). Tat stimulates transcription from the viral pro-
moter located within the long terminal repeat (LTR) of the
viral genome (Ratnasabapathy et al., 1990; Marciniak et
al., 1990; Laspia et al., 1989; Feinberg et al., 1991; Kao et
al., 1987; Majello et al., 1998). The primary effect of Tat is
to increase the processivity of RNA polymerase II (RNAP
II) that otherwise would prematurely terminate after the
synthesis of short transcripts (Ratnasabapathy et al.,
1990; Laspia et al., 1989; Feinberg et al., 1991; Kao et al.,
1987). Tat has been shown to functionally interact with
numerous components of the transcription complex, in-
cluding transcription factor IID (TFIID) TATA binding pro-
tein (TBP) (Kashanchi et al., 1994; Bohan et al., 1992),
TAFII250 (Weissman et al., 1998), RNAP II (Mavankal et
al., 1996; Cujec et al., 1997a; Garcia-Martinez et al., 1997),
the CDK7 subunit of TFIIH (Cujec et al., 1997b; Parada
and Roeder, 1996), and the CDK9/cyclin T1 complex
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452P-TEFb (Fujinaga et al., 1998; Mancebo et al., 1997; Wei et
al., 1998; Zhou et al., 1998; Zhu et al., 1997; Majello et al.,
1999; Bieniasz et al., 1999; Garber et al., 1998). To trigger
efficient RNA chain elongation, either in vivo or in vitro,
Tat must bind to the transactivation response (TAR) RNA
stem-loop structure, which forms from the initial portion
of the HIV-1 transcript (Berkhout et al., 1989; Ratna-
sabapathy et al., 1990; Bieniasz et al., 1998; Wimmer et
al., 1999; Fujinaga et al., 1999). It has been proposed that
Tat affects several sequential steps during the subse-
quent steps of transcription elongation. Tat may target
TFIIH directly and stimulate low-level phosphorylation of
the carboxy-terminal domain (CTD) at an early step in
transcription. Subsequently, Tat apparently recruits the
cyclin T1/CDK9 complex, P-TEFb, to facilitate RNAP II
elongation through the TAR RNA element. P-TEFb in-
duces hyperphosphorylation of the CTD, leading to a
transition from nonprocessive to processive transcription
elongation (Fujinaga et al., 1998; Jones, 1997; Mancebo
et al., 1997; Wei et al., 1998; Zhou et al., 1998; Zhu et al.,
1997; Isel and Karn, 1999).
The RNAP II-associated proteins RAP30 (26 kDa) and
RAP74 (56 kDa) are subunits of the transcription factor
TFIIF (Aso et al., 1992; Chang et al., 1993; Finkelstein et
al., 1992; Orphanides et al., 1996; Yonaha et al., 1993).
TFIIF can bind RNAP II directly and recruit the enzyme to
a preformed TFIID/TFIIB complex, which in turn stimu-
lates the rate of RNAP II elongation (Lei et al., 1998;
Orphanides et al., 1996). RAP74 is phosphorylated in vivo,
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453RAP74 PHOSPHORYLATION AND Tat-ACTIVATED TRANSCRIPTIONin accordance with the presence of several potential
phosphorylation sites in its primary sequence (Aso et al.,
1992; Finkelstein et al., 1992; Yonaha et al., 1997; Or-
hanides et al., 1996). Phosphorylation of RAP74 has
een reported to increase transcription initiation and
longation (Yonaha et al., 1997; Kitajima et al., 1994).
Several lines of evidence indicate that RAP74 is phos-
horylated by TFIID and that the TAFII250 subunit of
TFIID selectively phosphorylates RAP74 on serine resi-
dues (Dikstein et al., 1996; O’Brien and Tjian, 1998; Yo-
naha et al., 1997). The results of Dikstein et al. (1996)
indicate that TAFII250 contains N- and C-terminal kinase
domains. TAFII250-bearing mutations within the N-termi-
nal kinase domain exhibit a significantly reduced ability
to rescue ts13 cells that express a temperature-sensitive
TAFII250 (O’Brien and Tjian, 1998).
The results presented here demonstrate that TFIIF is
important for both basal and Tat-activated HIV-1 tran-
scription. Depletion of RAP74 from extracts obliterated
HIV-1 basal transcription and Tat transactivation. Impor-
tantly, the addition of reconstituted TFIIF from recombi-
nant RAP30 and RAP74 to the depleted extract resulted in
restoration of Tat transactivation. Our results further sug-
gest that RAP74 is phosphorylated by TAFII250 in Tat-
ctivated transcription. Phosphorylation of RAP74 corre-
ates with an enhanced transcription activity.
RESULTS
Tat stimulates the formation of transcriptionally active
reinitiation complexes on the biotinylated HIV-1 LTR
emplates. The following studies were initiated to identify
roteins that were involved in HIV-1 Tat transcription that
ight be regulated by posttranslational modification
uch as phosphorylation. HIV-1 LTR promoter templates
nt 2110 to 1168) were labeled with biotin at the up-
tream end (nt 2110) as described under Materials and
ethods. Biotinylated templates were incubated with
eLa nuclear extract in the absence or in the presence
f Tat as described previously (Kashanchi et al., 1994).
reinitiation complexes were subsequently isolated us-
ng streptavidin-coated magnetic beads and in vitro tran-
cription assays were performed. In the absence of Tat,
low level of basal HIV-1 transcription was observed
Fig. 1A, lane 1). The addition of increasing amounts of
at protein to the preincubation mix significantly in-
reased transcription from the HIV-1 promoter (Fig. 1A,
anes 2–5). Consistent with previous results, optimum Tat
ransactivation was observed when approximately 100
g of Tat was added to the reaction (Fig. 1A, lane 4).
The specificity of the in vitro transcription system is
demonstrated in Figs. 1B through 1D. Tat failed to acti-
vate transcription from either a HIV-1 TATA box mutant or
a TAR mutant template (Figs. 1B and 1C). Furthermore,
transactivation was not observed when a Tat transacti-
vation mutant, Tat72 C22G, was added to the transcrip-tion assay (Fig. 1D). Tat transactivation was sensitive to
the addition of DRB and required the Tat-associated
kinase P-TEFb (data not shown). These results, consis-
tent with previous observations, suggest that preinitia-
tion complexes formed in the presence of Tat have the
factors required for activated transcription elongation
(Isel and Karn, 1999). Moreover, the effect of Tat on
transcriptional elongation may be observed with rela-
tively short transcripts (Cujec et al., 1997b; Okamoto et
al., 1996; Isel and Karn, 1999).
RAP74 was specifically phosphorylated during Tat-ac-
tivated transcription from the HIV-1 LTR. The ability to
isolate preinitiation complexes allowed us to ask ques-
tions regarding the posttranslational modification of pro-
teins during Tat transactivation. Specifically, the phos-
phorylation of the RNAP II CTD and other general tran-
FIG. 1. Tat stimulated transcription from HIV-1 LTR. In vitro transcrip-
tion reactions were performed with the purified preinitiation complexes
and the transcripts were labeled with [a-32P]UTP. (A) Tat stimulated
transcription from the wild-type (WT) HIV-1 LTR. (B) No productive
transcription from the TATA box mutant HIV-1 LTR (indicated as “Mut”)
as detected. (C) Tat was not able to activate transcription from the
AR mutant (TM26) HIV-1 LTR. (D) Comparison of the transactivation
ctivities of wild-type GST–Tat72 and GST–Tat72 C22G proteins in the
n vitro transcription assay.scription factors during Tat transactivation has been
analyzed. Western blot analysis demonstrated that the
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454 ZHOU ET AL.primary species of RNAP II bound to the preinitiation
complexes was unphosphorylated RNAP IIa (Fig. 2A,
lanes 1 and 2). When nucleoside triphosphates were
added to the reaction and transcription was allowed to
proceed for 60 min, Western blot analysis of the elonga-
tion complexes demonstrated that RNAP II had been
converted to the hyperphosphorylated RNAP IIo (Fig. 2A,
lane 3), consistent with previous observations.
We next investigated whether general transcription
factors were phosphorylated during Tat transactivation of
the HIV-1 LTR. Preinitiation complexes were isolated and
incubated with nucleoside triphosphates and [g-32P]ATP.
FIG. 2. Phosphorylation of RNAP II CTD and RAP74 in Tat-activated
ranscription. (A) Phosphorylation of RNAP II CTD in Tat transactivated
ranscription. Western blot analysis of Tat preinitiation complex (PIC)
nd Tat transcription elongation complex (TEC). Preinitiation com-
lexes were assembled by incubating HeLa nuclear extract, biotinyl-
ted HIV-1 LTR templates, and poly(dI–dC) in the presence of Tat.
ranscription reactions were initiated by the addition of nucleotides
nd allowed to incubate for 60 min at 30°C. To analyze the states of
NAP II CTD in the stages of transcription, the samples were fraction-
ted on a 4% SDS polyacrylamide gel and then transblotted onto an
mmobilon-P membrane (Millipore). RNAP II was detected with anti-
NAP II CTD antibody. (B) RAP74 phosphorylation in Tat-activated
ranscription. Transcription reactions were performed with the purified
reinitiation complexes. The proteins phosphorylated during the tran-
cription were labeled with [g-32P]ATP and immunoprecipitated with
orresponding antibodies: lanes 1 and 2 with normal IgG (as controls),
anes 3 and 4 with anti-TFIIEa (p56) antibody, lanes 5 and 6 with
nti-TFIIH (p62) antibody, lanes 7 and 8 with anti-RAP74 antibody;
dd-numbered lanes without Tat and even-numbered lanes with Tat.
C) Comparison of the abilities of wild-type GST-Tat72 and GST-Tat72
22G proteins to induce phosphorylation of RAP74 in the in vitro
ranscription assay. (Top) RAP74 phosphorylation; (bottom) Coomassie
lue stain of the input Tat proteins.ranscription reactions were then immunoprecipitated
ith control IgG or antibody specific for TFIIEa, the p62
i
eubunit of TFIIH, or the RAP74 subunit of TFIIF. The
esults of this assay suggest that RAP74 was phosphor-
lated in transcription reactions containing the Tat pro-
ein (Fig. 2B, lanes 7 and 8). No phosphorylation of
ranscription factors such as TFIIEa and TFIIH p62 was
found in the absence or in the presence of Tat (Fig. 2B,
lanes 3, 4, 5, and 6). Western blot analysis of the immu-
noprecipitates demonstrated that comparable amounts
of TFIIE, TFIIH p62, and RAP74 were precipitated from
the transcription reactions (data not shown).
As a control for this experiment, we have analyzed the
ability of the Tat72 C22G mutant to induce phosphoryla-
tion (Fig. 2C). The results presented in Fig. 2C demon-
strate that RAP74 is phosphorylated in the presence of
wild-type Tat72 (lane 3), but not the Tat transactivation-
defective protein Tat72 C22G (lane 2). A Coomassie blue
stain of the input Tat proteins demonstrates that an equal
amount of protein was added to the reaction (Fig. 2C,
bottom).
RAP74 was specifically phosphorylated by TAFII250 in
the Tat preinitiation complexes. It has been reported that
the TAFII250 kinase phosphorylates RAP74 (Dikstein et
l., 1996). To determine whether the TAFII250 kinase was
responsible for phosphorylation of RAP74 in the in vitro
assays, HeLa nuclear extract was preincubated with
anti-TAFII250 for 60 min at 4°C. The anti-TAFII250 anti-
ody specifically blocks the kinase activity of TAFII250,
but does not affect incorporation of TFIID into the preini-
tiation complex (data not shown). In parallel assays,
antibodies to CDK7 and CDK9 were added to the extract.
Biotinylated HIV-1 LTR templates and Tat protein were
then added to the extract. After incubation for 30 min at
30°C, the preinitiation complexes were purified with
streptavidin-coated magnetic beads. [g-32P]ATP was
added to the purified preinitiation complexes and the
reaction was carried out for 30 min at 30°C. RAP74 was
subsequently immunoprecipitated with anti-RAP74 anti-
body. RAP74 was not phosphorylated when the extract
had been pretreated with TAFII250 antibody (Fig. 3, lane
2). In contrast, phosphorylated RAP74 was observed
when the extracts were pretreated with either anti-CDK7
or anti-CDK9 antibody (Fig. 3, lanes 1, 3, and 4). These
results suggest that the TAFII250 kinase specifically
hosphorylates RAP74 in the Tat preinitiation complex.
Depletion of RAP74 from nuclear extracts significantly
ecreases HIV-1 transcription. To investigate the func-
ional role of RAP74 phosphorylation in Tat transactiva-
ion, RAP74-depleted HeLa nuclear extract was pre-
ared. Western blot analysis of the extracts before and
fter depletion demonstrate that RAP74 was removed
rom the extracts treated with anti-RAP74, but not control
ntibody (Fig. 4A). Subsequently, the extracts were used
or in vitro transcription assays with HIV-1 LTR templates
n the absence or in the presence of Tat. Removal of the
ndogenous RAP74 from HeLa nuclear extract obliter-
ct
m
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teins were labeled with [g- P]ATP. Phosphorylated RAP74 was im-
munoprecipitated with anti-RAP74 antibody.
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455RAP74 PHOSPHORYLATION AND Tat-ACTIVATED TRANSCRIPTIONated both basal and Tat-activated transcription from the
HIV-1 LTR (Fig. 4B, lanes 2 and 7).
To demonstrate that the loss of transcription activity
was due to depletion of RAP74, and not another general
transcription factor, RAP30 and RAP74 were overex-
pressed and purified from bacteria (Imhof et al., 1997).
Subsequently, the RAP30/RAP74 TFIIF complex was re-
constituted. Addition of purified, unphosphorylated
RAP30/RAP74 to the RAP74-depleted HeLa nuclear ex-
tract restored basal transcription and Tat transactivation
(Fig. 4B, lanes 4 and 9). Importantly, the results presented
in Fig. 4C demonstrate that the exogenous RAP74 was
rapidly phosphorylated in the reconstituted reactions
containing Tat (Fig. 4C, lane 4), which exhibited a high
level of transcription (Fig. 4B, lane 9). In contrast, reac-
tions that did not contain Tat failed to phosphorylate the
exogenous RAP30/RAP74 complex (Fig. 4C, lane 2) and
exhibited a low level of transcription (Fig. 4B, lane 4).
These results demonstrate that RAP74 is important for
basal and Tat-activated transcription from the HIV-1 LTR.
In the presence of Tat, phosphorylation of RAP74 is
LTR and AdML. (A) Western blot analysis of RAP74 in mock-depleted
clear extract). (B) Phosphorylated RAP74 enhanced transcription from
uclear extract (lanes 1 and 6) or RAP74-depleted HeLa nuclear extract
/RAP74 (unphosphorylated RAP74) or RAP30/RAP74-P (phosphorylated
250 was added as controls in lanes 3 and 8). (C) The exogenous RAP74
reactions were performed with RAP74-depleted HeLa nuclear extract
P74 phosphorylated during transcription from HIV-1 LTR was labeled
ted HeLa nuclear extract was complemented with RAP30/RAP74 in the
epleted HeLa nuclear extract was used as control in the presence of
AP74 stimulated the transcription activity of the adenovirus major lateFIG. 3. RAP74 phosphorylation by TAFII250 in Tat preinitiation
omplexes. HeLa nuclear extract (15 ml) was incubated for 60 min at
4°C with 3 ml of anti-TAFII250, anti-CDK7, or anti-CDK9 antibody,
respectively (normal IgG as a control). Biotinylated HIV-1 LTR tem-
plates (1.0 mg) and Tat protein (100 ng) were then added to pre-
reated extracts and the mixtures were allowed to incubate for 30
in at 30°C. Preinitiation complexes were separated with strepta-
idin-coated magnetic beads. Kinase reactions were performed with
he purified preinitiation complexes and the phosphorylated pro-
32FIG. 4. Phosphorylated RAP74 enhanced the transcription activities of HIV-1
eLa nuclear extract and RAP74-depleted HeLa nuclear extract (NE, HeLa nu
IV-1 LTR. Transcription reactions were performed with mock-depleted HeLa n
lanes 2–5 and 7–10) in the absence (2) or in the presence (1) of Tat. RAP30
AP74) was added to RAP74-depleted reactions as indicated in the figure (TAFII
was phosphorylated during transcription in the presence of Tat. Transcription
complemented with RAP30/RAP74 or mock-depleted HeLa nuclear extract. RA
with [g-32P]ATP and immunoprecipitated with anti-RAP74 antibody. RAP74-deple
resence of HIV-1 LTR templates without (lane 2) or with (lane 4) Tat. Mock-d
IV-1 LTR templates without (lane 1) or with (lane 3) Tat. (D) Phosphorylated Rlyzed in extracts depleted with anti-RAP74 antibody and reconstituted
in kinase assay.
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456 ZHOU ET AL.observed, which correlates with a high level of transcrip-
tion activity.
For comparison, similar assays were performed with
the adenovirus major late promoter. Depletion of RAP74
from the extract abolished basal promoter activity (Fig.
4D, lanes 1 and 2). Addition of purified RAP74/RAP30 to
the depleted extract restored transcription (Fig. 4D, lane
4). Addition of phosphorylated RAP74/RAP30 to the
RAP74-depleted extract further stimulated transcription
(Fig. 4D, lane 5). Thus, the basal AdML and HIV-1 pro-
moters behaved similarly in that addition of phosphory-
lated RAP74/RAP30 increased transcription to an artifi-
cially high level, suggesting that phosphorylation of
RAP74 is not an efficient process in the basal transcrip-
tion complex.
Correlation between RAP74 phosphorylation and HIV-1
transcription activity. These results suggest that one lim-
itation in HIV-1 transcription is the ability to phosphory-
late the RAP74 subunit of TFIIF. To test this hypothesis,
recombinant RAP74 was kinased with purified recombi-
nant TAFII250 (Imhof et al., 1997) and subsequently re-
onstituted with RAP30. Addition of an equivalent
mount of phosphorylated RAP30/RAP74-P (Fig. 4E) to
he RAP74-depleted HeLa nuclear extract resulted in
ctivation of basal transcription (Fig. 4B, lanes 4 and 5).
ue to the ability of the Tat preinitiation complex to
apidly phosphorylate RAP74, addition of phosphorylated
AP30/RAP74-P did not increase Tat transactivation
bove the level seen with unmodified RAP74 (Fig. 4B,
anes 9 and 10). These studies demonstrate a strong
orrelation between RAP74 phosphorylation and HIV-1
ranscription activity.
These results suggest that RAP74 is important for
asal and Tat-activated transcription from the HIV-1 LTR.
he basal HIV-1 transcription complex lacks the ability to
nduce TAFII250 kinase activity on RAP74. In the pres-
ence of Tat, TAFII250 kinase activity toward RAP74 is
induced, providing an essential step in the cascade of
events leading to the formation of an efficient transcrip-
tion elongation complex. Moreover, it is likely that this
step precedes the TAR-dependent Tat/P-TEFb hyper-
phosphorylation of the RNAP II CTD.
DISCUSSION
The results presented in this study demonstrate that
phosphorylation of the RAP74 subunit of the transcription
factor TFIIF is increased during Tat transactivation. Kita-
jima et al. (1994) have analyzed the regulation of TFIIF
activity by phosphorylation by comparing the biochemi-
cal properties of alkaline phosphatase-treated TFIIF with
those of native or bacterially expressed factors. Both the
transcription initiation and the elongation stimulating ac-
tivities of the phosphatase-treated TFIIF decreased to
15–20% of the native form under conditions in which the
amount of TFIIF was rate-limiting. The decrease in tran-scription elongation was likely due to the fact that phos-
phatase-treated TFIIF bound to RNA polymerase less
efficiently than native protein. In this regard, it is inter-
esting to consider the results of Zawel et al. (1995), who
demonstrated that TFIIF is unique in that it is the only
basal transcription factor detected in the elongation
complex. Following its release from the initiation com-
plex, TFIIF has the ability to reassociate with RNAP II.
Phosphorylation of RAP74 may facilitate the reassocia-
tion of the transcription factor with the elongation com-
plex. In the event that the polymerase pauses, TFIIF may
facilitate passage through the pause. It is interesting to
speculate that phosphorylated TFIIF may help to “jump-
start” stalled or paused transcription complexes in which
P-TEFb has phosphorylated the RNAP II CTD. In this
model, phosphorylated TFIIF would not be absolutely
required, but would facilitate the process of release of
transcription elongation complexes. Phosphorylation of
the RNAP II CTD by P-TEFb, on the other hand, is an
absolute requirement for the paused complex to be re-
leased.
The 517-amino-acid (aa) sequence of RAP74 can be
divided into three regions: (i) a highly basic N-terminal
domain with significant globular structure (aa 1 to 217);
(ii) an overall acidic, highly charged central region lack-
ing in hydrophobic amino acids but rich in polar amino
acids (aa 218 to 398); and (iii) a very basic C-terminal
domain with globular structure (aa 399 to 517) (Aso et al.,
1992; Finkelstein et al., 1992; Lei et al., 1998). The N-
erminal domain is important for RAP30 binding (Wang
nd Burton, 1995; Yonaha et al., 1993), preinitiation com-
lex assembly, and elongation (Lei et al., 1998). The
-terminal domain makes contact with TFIIB and RNAP II
nd stimulates the activity of a CTD phosphatase (Cham-
ers et al., 1995). Of significance, sequences within the
entral region affect accessibility of the C-terminal do-
ain with RNAP II (Wang and Burton, 1995). The evi-
ence that serine residues within amino acids 217–224,
ocated in the central region of RAP74, are phosphory-
ated by TAFII250 (Dikstein et al., 1996; Yonaha et al.,
1997) suggests the possibility that the functional role of
RAP74 phosphorylation by TAFII250 may be related to
increasing the interaction with RNAP II. This interpreta-
tion would be consistent with the results of Kitajima et al.
(1994), who reported that alkaline phosphatase treatment
of RAP74 reduced the interaction with RNAP II.
The general TFIID, which is composed of TBP and
multiple TBP-associated factors (TAFs) (Goodrich and
Tjian, 1994; Orphanides et al., 1996), is one of the central
components involved in regulation of RNAP II transcrip-
tion (Orphanides et al., 1996; Sauer et al., 1995; Verrijzer
and Tjian, 1996). The largest component of the TFIID
protein complex, TAFII250, provides the core scaffold
upon which TBP and the other TAFs are assembled,
forming a stable holo-TFIID complex (Weinzierl et al.,
1993). Of interest, TAFII250 is identical to the cell cycle
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457RAP74 PHOSPHORYLATION AND Tat-ACTIVATED TRANSCRIPTIONgene 1 (CCG1), a gene able to complement the late G1
arrest observed in the temperature-sensitive mutant
hamster cell line ts13 (Hisatake et al., 1993; Ruppert et
al., 1993). There are multiple domains within the TAFII250
rotein that appear to carry out potentially different func-
ions. First, several lines of evidence suggest that
AFII250 is a major scaffold protein of TFIID and is thus
involved in both core–promoter recognition and coacti-
vator function through protein–protein interactions (Ver-
rijzer et al., 1995; Verrijzer and Tjian, 1996; Wang and
Tjian, 1994; Wang et al., 1997). Second, both human
TAFII250 and Drosophila TAFII250 contain a histone
acetyltransferase domain that can acetylate histones H3,
H4, and H2A (Mizzen et al., 1996). Finally, hTAFII250
ontains two independent serine/threonine kinase do-
ains, located in the N- and C-terminal regions of the
rotein (Dikstein et al., 1996). Neither of these domains
resembles other known kinases, suggesting that they
may represent members of a novel class of kinases. Both
the N- and the C-terminal kinase domains of TAFII250
can phosphorylate RAP74, but efficient phosphorylation
of RAP74 requires the combined action of both domains.
It is interesting to consider that the kinase activity of
TAFII250 may be induced by an activator(s). Along these
lines, Weissman et al. (1998) have reported that Tat
interacts with TAFII250 and regulates acetyl transferase
nzyme activity. Preliminary evidence suggests that Tat
ncreases the kinase activity of purified TAFII250 on
RAP74 (data not shown). Experiments are under way to
examine the effect of Tat on TAFII250 kinase activity in
the TFIID complex.
Kato et al. (1992) have previously analyzed the impor-
tance of TFIIF in HIV-1 basal and Tat-activated transcrip-
tion. Preincubation of nuclear extracts with an antibody
raised against recombinant RAP74 decreased both basal
and Tat-activated transcription. The results reported in
our present study extend these findings by demonstrat-
ing that phosphorylation of the RAP74 subunit of TFIIF
occurs only in the presence of Tat and correlates with
increased transcriptional activity. TAFII250 has been re-
ported to phosphorylate RAP74 at serine residues in
amino acids 217–224. It will be of interest to develop
mutations within the phosphorylation domain of RAP74
(amino acids 217–224) (Dikstein et al., 1996; Yonaha et
l., 1997) and analyze their effect on basal and Tat-
ctivated transcription. Moreover, these mutations would
e important in determining the effect of phosphorylation
f TFIIF on transcription activity using other promoters.
It is becoming increasingly apparent that RAP74 phos-
horylation appears to increase TFIIF transcription ac-
ivity. Kitajima et al. (1994) have shown that RAP74, but
ot RAP30, was extensively phosphorylated in vivo and
hat TFIIF transcription initiation and elongation activities
ere stimulated by phosphorylation of RAP74. Consis-ent with these observations, Yonaha et al. (1997) have
hown that the cell-cycle-dependent phosphorylation of
l
IAP74 increases in vitro transcription activity. In view of
he fact that the RAP74 binding site of TAFII250 is re-
quired to rescue ts13 cells, the cell-cycle-dependent
phosphorylation of RAP74 may play an important role in
cell cycle regulation. The viral transactivator Tat may
accentuate this function of TAFII250 and stimulate HIV-1
ranscription. Given that mutations in TBP that affect Tat
ransactivation correlate with the ability of TBP to bind
AFII250, it is likely that the multisubunit TFIID complex,
and not TBP, is involved in HIV-1 transcription (Pender-
grast et al., 1996). In view of the results presented in this
article, the kinase activity TAFII250 may also play a sig-
nificant role in the efficiency of Tat transactivation.
MATERIALS AND METHODS
Biotinylation of template DNAs. The wild-type, TATA
box mutant, and TAR mutant TM26 (Boris-Lawrie et al.,
1992) HIV-1 LTR templates (nt 2110 to 1168) were am-
plified by PCR with the forward primer 59 biotinylated-TAT
GGA TTT ACA AGG GAC TTT C-39 and the reverse primer
59-GAT CCG ATT ACT AAA AGG G-39. The primers were
synthesized and biotinylated by Lofstrand Labs Limited.
Isolation of preinitiation complexes. Assembly reac-
tions (50 ml) contained 25 ml of HeLa nuclear extract, 1.0
mg of biotinylated HIV-1 LTR template, 1.0 mg of poly(dI–
dC), purified Tat protein in 13 in vitro transcription (IVT)
buffer [IVT buffer: 50 mM KCl, 6.25 mM MgCl2, 20 mM
EPES (pH 7.9), 2 mM DTT, 0.5 mM EDTA (pH 8.0), 10 mM
nSO4, 10 mM creatine phosphate, 100 mg/ml of creatine
kinase, and 8.5% glycerol]. After a 30-min incubation at
30°C, streptavidin-coated magnetic beads (Dynabeads,
Dynal) preequilibrated in binding buffer [20 mM HEPES
(pH 7.9), 80 mM KCl, 10 mM MgCl2, 2 mM DTT, 10 mM
ZnSO4, 100 mg/ml bovine serum albumin (BSA), 0.05%
Nonidet-P40 (NP-40), and 10% glycerol] were added to
the reaction mixtures. The reaction mixes were then
incubated for an additional 30 min at 30°C. The immo-
bilized templates were harvested using a magnetic stand
and the preinitiation complexes were washed exten-
sively with 13 IVT buffer. IVT and Western blot analysis
were performed using the purified preinitiation com-
plexes assembled on the immobilized templates.
In vitro transcription with the purified preinitiation com-
plexes. In vitro transcription reactions (100 ml) were set
up by resuspending the purified preinitiation complexes
in 100 ml of 13 IVT buffer, 50 mM ATP, 50 mM CTP, 50 mM
GTP, 10 mCi [a-32P]UTP, and 10 units of RNasin (Pro-
ega). The transcription reaction mixtures were incu-
ated for 60 min at 30°C. RNA transcripts were purified
nd fractionated by electrophoresis on a 6% denaturing
olyacrylamide gel containing 7 M urea in 13 TBE. Theabeled mRNA products were detected with a Phosphor-
mager.
Ii
I
N
a
c
S
A
c
h
a
r
R
t
l
i
T
0
i
B
458 ZHOU ET AL.Western blot analysis of the purified preinitiation com-
plexes. The purified preinitiation complexes, assembled
on the immobilized templates, were heated in SDS load-
ing buffer for 10 min at 100°C. The released proteins
were fractionated by electrophoresis on 4% SDS–poly-
acrylamide gels and then transblotted onto 0.45 mM
Immobilon-P membranes (Millipore). RNAP II was de-
tected with a specific antibody against the RNAP II CTD
(Santa Cruz Biotechnology).
Immunoprecipitation. To detect phosphorylated pro-
teins during transcription, reaction mixtures (100 ml) con-
taining the purified preinitiation complexes, 50 ml of 23
VT buffer, 50 mM CTP, 50 mM GTP, 50 mM UTP, 10
mCi[g-32P]ATP, and 10 units of RNasin (Promega) were
ncubated for 60 min at 30°C. Four hundred microliters of
P buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1%
P-40, 0.1% SDS, 1 mM EDTA (pH 8.0), 5% glycerol] was
dded to the reaction mixtures and the streptavidin-
oated beads were separated using a magnetic stand.
ix microliters of anti-RAP74, anti-TFIIEa, and anti-TFI-
IH(p62) antibodies was added to the supernatants and
the mixtures were gently rocked overnight at 4°C. Pro-
tein A/Sepharose CL-4B beads were added to the mix-
tures containing antigen/antibody complexes and the
mixtures were incubated for 60 min at 4°C with rocking.
The protein A/antibody/antigen complexes were har-
vested and washed four times with RIPA buffer [50 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS]. The samples were analyzed by
4–20% SDS–polyacrylamide gel electrophoresis and
PhosphorImager.
Assay of RAP74 phosphorylation in purified preinitia-
tion complexes. Fifteen microliters of HeLa nuclear ex-
tract and 3 ml of anti-TAFII250, anti-CDK7, or anti-CDK9
antibodies were mixed and incubated for 60 min at 4°C.
Preinitiation complexes were assembled by adding 1.0
mg biotinylated HIV-1 promoter template and 100 ng Tat
protein to the mixtures. After a 30-min incubation at
30°C, the preinitiation complexes were isolated with
streptavidin-coated magnetic beads. Kinase reactions
were performed by mixing the purified preinitiation com-
plexes with 10 mCi [g-32P]ATP in a total volume of 100 ml.
fter incubation for 30 min at 30°C, the preinitiation
omplexes were purified using the magnetic stand. Five
undred microliters of IP buffer was added to the tubes
nd the mixtures were incubated for 120 min at 4°C with
ocking. The supernatants were collected and anti-
AP74 antibody (Santa Cruz Biotechnology) was added
o the supernatants to immunoprecipitate phosphory-
ated RAP74.
TAFII250 kinase assay. Kinase assays were performed
n 30-ml reaction mixtures containing 40 ng RAP74, 20 ng
TAFII250, 10 mCi [g-
32P]ATP, and 13 kinase buffer [50 mMris–HCl (pH 7.5), 5 mM DTT, 5 mM MnCl2, 4 mM MgCl2,
40 mM KCl, 0.25 mg/ml BSA, 2% glycerol, and 0.1%NP-40]. The reactions were incubated for 30 min at 30°C
and analyzed on 4–20% SDS–polyacrylamide gel.
Immunodepletion of RAP74 from HeLa nuclear extract.
HeLa nuclear extract (50 ml) in 0.8 M KCl buffer D [20 mM
HEPES (pH 7.9), 15% glycerol, 800 mM KCl, 10 mM MgCl2,
.2 mM EDTA (pH 8.0), 0.1% NP-40, and 1 mM DTT] was
ncubated with 20 ml of Protein A–Sepharose beads to
which anti-RAP74 antibodies had been prebound (10 mg
of IgG, Santa Cruz Biotechnology). Antibody-bound com-
plexes were removed by centrifugation. After the proce-
dure was repeated twice, depleted nuclear extract was
dialyzed against 0.1 M KCl buffer D and assayed by
Western blot analysis.
Transcription activity assay of phosphorylated RAP74.
RAP74 was phosphorylated using purified TAFII250 in
vitro, as above. RAP30/RAP74-P (phosphorylated) com-
plexes were formed by mixing purified, phosphorylated
RAP74 with purified RAP30. Transcription reactions were
performed using RAP74-depleted HeLa nuclear extract
complemented with RAP30/RAP74 or RAP30/RAP74-P.
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